Influence of neuroblastoma stage on serum‐based detection of MYCN amplification
Pediatric Blood & Cancer2009Vol. 53(3), pp. 329–331
Citations Over TimeTop 25% of 2009 papers
Valérie Combaret, Michael D. Hogarty, Wendy B. London, Patrick McGrady, Isabelle Iacono, Stéphanie Bréjon, Katrien Swerts, Rosa Noguera, Nicole Groß, Raphaël F. Rousseau, Alain Puisieux
Abstract
Our results show that the sensitivity of the serum-based MYCN DNA sequence determination depends on the stage of the disease. However, this simple, reproducible assay may represent a reasonably sensitive and very specific tool to assess tumor MYCN status in cases with stage 3 and metastatic disease for whom a wait and see strategy is often recommended.
Related Papers
- → The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma(2006)88 cited
- → The Characteristics of Mediastinal Neuroblastoma(2000)40 cited
- → Low complex ganglioside expression characterizes human neuroblastoma cell lines(2005)38 cited
- → Excretion of catecholamines, their precursors and metabolites in patients with neuroblastoma and Ewing's tumour(1978)1 cited
- Current Clinical Trials in Neuroblastoma(2002)